Proactive Investors - Run By Investors For Investors

ANGLE liquid biopsy crucial to prostate cancer breakthrough

The Parsortix system, which is used to harvest circulating tumour cells from the blood stream associated with cancer, helped researchers from the Queen Mary University of London's Barts Cancer Institute find two rare cells.
ANGLE liquid biopsy crucial to prostate cancer breakthrough
The advance may allow doctors tailor treatment for patients with the killer disease

Med-tech firm ANGLE PLC (LON:AGL,OTCQX:ANPCY) saw its shares leap today on news its liquid biopsy test has been pivotal in a breakthrough that could transform the treatment of prostate cancer.

The group said the Parsortix system, which is used to harvest circulating tumour cells (CTCs) from the blood stream associated with cancer, helped researchers from the Queen Mary University of London's Barts Cancer Institute (BCI) find two rare cells.

The first is known as a megakaryocyte and the BCI team was able to link its presence to patients who lived longer after being diagnosed with the killer disease. Parsortix was also able harvest mesenchymal CTCs, which are linked to a poor outcomes.

WATCH: ANGLE's Andrew Newland on 'very exciting' liquid biopsy breakthrough

The BCI study of 40 people found that combining these two factors enabled the identification of patients who are 10-times more likely to die of their disease in the short-term. 

That may sound depressing, but armed with this knowledge doctors may be able to develop targeted treatments, potentially improving patient outcomes.

"This is a key breakthrough for ANGLE's Parsortix system showing further unique capabilities to harvest both rare megakaryocyte cells and mesenchymal CTCs in patient blood that play an essential role in the process of metastasis, which is responsible for over 90% of cancer deaths worldwide,” said ANGLE founder and chief executive Andrew Newland. 

“The findings of this study are of great medical potential, demonstrating an ability to identify patients most at risk of aggressive prostate cancer and a higher rate of mortality and consequently most in need of intensive treatment."

In late afternoon trading, ANGLE shares were up 17.7%, or 11,25p at  74.75p.

 -- Adds share price, video link --

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

parsortix
January 03 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
researcher filling a tray of samples
December 14 2018
The company has two clinical trials underway and is well funded to achieve its immediate ambitions

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use